Cytotechnology
ISSN 0920-9069 · Springer Science+Business Media · Netherlands · active 1987–2026
Metrics
- Best Scimago quartile (2025)
- Q3
- Cites per paper (2y)
- 1.5
- SJR
- 0.534
- h-index
- 94
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric (how the two differ). Citation rates differ enormously between fields, so compare within a discipline. What the other figures mean: journal quartile, SJR, h-index and article processing charge.
Data as of 1 November 2026 (venue index build).
Scimago Journal Rank 2025
In the Scimago Journal Rank 2025 edition, Cytotechnology is Q3 in 4 of its 5 subject categories and Q4 in the other 1. Its best category quartile is Q3.
| Subject category | Quartile | Rank in category |
|---|---|---|
| Clinical Biochemistry | Q3 | #75 of 125 |
| Bioengineering | Q3 | #101 of 165 |
| Biotechnology | Q3 | #163 of 320 |
| Biomedical Engineering | Q3 | #172 of 328 |
| Cell Biology | Q4 | #230 of 297 |
- Cites per document (2 years, Scopus)
- 2.43
- Documents indexed in 2025 (Scopus)
- 192
OpenAlex counts about 1.5 citations per paper over two years; Scopus, through Scimago, counts 2.43 per document. The two databases index different journals, documents and citations, so the figures differ. Neither is a Clarivate Journal Impact Factor.
The quartile is the one Scimago prints for each category. Rank is the journal's position by SJR among the journals Scimago lists in that category (#1 is the highest); “—” means we hold no rank consistent with that quartile. The document count is what Scopus indexed that year, which can be lower than a journal's full output. Source: SCImago Journal Rank 2025 edition, from Scopus data (scimagojr.com, CC BY-NC).
Cytotechnology is Q3 in 4 of its 5 Scimago subject categories (2025 edition; best category Clinical Biochemistry: Q3, #75 of 125), with SJR 0.534 (Scimago) and an h-index of 94 (OpenAlex). Listed in Scopus, Web of Science, PubMed.
Is this the right journal for your paper?
The AI Journal Finder ranks the best-matched journals for your paper’s topic — with tier, open access, citation rate and predatory flags. Free to start.
Responding time
- Submission to acceptance
- 81 days (median)Estimated from our library (25 papers)
- Acceptance to publication
- 14 days (median)Estimated from our library (22 papers)
- Submission to publication
- 122 days (median)Estimated from our library (22 papers)
Turnaround figures are indicative, not a guarantee: DOAJ values are self-reported by the journal (average weeks, submission to publication); library estimates are medians of the received/accepted dates printed in papers we hold. Editorial times vary by article type and season — confirm on the journal’s own site.
Indexing & access
- Indexed in
- ScopusWeb of SciencePubMed
- Access status:
- hybrid. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Cytotechnology a predatory journal?
Our screening does not flag Cytotechnology. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.
Is Cytotechnology indexed in Scopus or Web of Science?
Per our venue index, Cytotechnology appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is the impact factor of Cytotechnology?
Papers in Cytotechnology are cited about 1.5 times each within two years of publication, and Scimago places it in Q3, with an h-index of 94. Those are the open equivalents: the Clarivate Journal Impact Factor is a proprietary metric we neither compute nor license, so we show the two-year citation rate and Scimago quartile instead — they answer the same question of how heavily the journal is cited. A citation rate is a property of a field as much as of a journal.
What Scimago quartile is Cytotechnology (Q1, Q2, Q3, or Q4)?
In the Scimago Journal Rank 2025 edition, Cytotechnology is Q3 in 4 of its 5 subject categories and Q4 in the other 1. By category: Clinical Biochemistry: Q3, #75 of 125; Bioengineering: Q3, #101 of 165; Biotechnology: Q3, #163 of 320; Biomedical Engineering: Q3, #172 of 328; Cell Biology: Q4, #230 of 297. Its best category quartile is Q3. Quartiles split the journals in a subject category into four equal groups by SJR, so Q1 is the most-cited quarter and Q4 the least; Cytotechnology is cited about 1.5 times per paper over two years, with an h-index of 94.
What is the Web of Science (JCR) quartile of Cytotechnology?
The Web of Science quartile comes from Clarivate's Journal Citation Reports (JCR), a proprietary product we neither license nor compute — so we cannot state a JCR quartile for Cytotechnology. The open equivalent is its best Scimago quartile, Q3 in Clinical Biochemistry and 3 other categories, derived from Scopus citation data. Because JCR ranks against Web of Science and Scimago against Scopus, the two can differ, so check Clarivate's site directly if you need the JCR quartile specifically.
Is Cytotechnology open access?
Our index records its access status as "hybrid". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.
How long does Cytotechnology take to publish a paper?
Submission to acceptance for Cytotechnology takes about 81 days (median) — Estimated from our library (n=25 papers). Treat it as indicative rather than a guarantee: editorial times vary by article type, reviewer availability and season, and a self-reported figure is the journal's own. We do not hold a peer-review acceptance rate for Cytotechnology.
Ready to submit? Tools for your next paper
Similar venues
- Journal of Computational BiologyQ2 · Mary Ann Liebert, Inc.
- Medical Molecular MorphologyQ2 · Springer Science+Business Media
- YeastQ2 · Wiley
- Natural Product ResearchQ3 · Taylor & Francis
- Critical Reviews in Eukaryotic Gene ExpressionQ4 · Begell House
- International Journal of Data Mining and BioinformaticsQ4 · Inderscience Publishers
Compare it with its peers: Ranked Molecular Biology journals — ranked by Scimago quartile and cites per paper, predatory venues excluded.